ClinVar Miner

Submissions for variant NM_000135.4(FANCA):c.1874G>C (p.Cys625Ser)

gnomAD frequency: 0.00230  dbSNP: rs139235751
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 19
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000255908 SCV000321624 uncertain significance not specified 2017-01-24 criteria provided, single submitter clinical testing The C625S variant in the FANCA gene has been previously reported in an individual with Fanconi anemia who also harbored a multi-exon FANCA deletion; however, the phase of these two variants was not confirmed, as parental testing was not performed (Castella et al., 2011). Although not present in the homozygous state, the NHLBI ESP Exome Sequencing Project reports C625S was observed in 27/8600 (0.31%) alleles from individuals of European background, indicating it may be a rare variant in this population. The C625S variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is conserved across species, and in silico analysis predicts this variant is probably damaging to the protein structure/function. We interpret C625S as a variant of uncertain significance.
Eurofins Ntd Llc (ga) RCV000255908 SCV000343524 likely benign not specified 2016-08-01 criteria provided, single submitter clinical testing
Invitae RCV000475267 SCV000558869 benign Fanconi anemia 2024-02-01 criteria provided, single submitter clinical testing
Genetic Services Laboratory, University of Chicago RCV000255908 SCV000594639 uncertain significance not specified 2016-11-02 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000255908 SCV000603559 uncertain significance not specified 2017-04-12 criteria provided, single submitter clinical testing
Mendelics RCV000989672 SCV001140204 uncertain significance Fanconi anemia complementation group A 2019-05-28 criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV000989672 SCV001278635 uncertain significance Fanconi anemia complementation group A 2017-04-27 criteria provided, single submitter clinical testing This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance.
Genome-Nilou Lab RCV000989672 SCV001652749 uncertain significance Fanconi anemia complementation group A 2021-05-18 criteria provided, single submitter clinical testing
Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden RCV001800637 SCV002010571 uncertain significance not provided 2021-11-03 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000255908 SCV002047065 benign not specified 2021-05-13 criteria provided, single submitter clinical testing
Sema4, Sema4 RCV000475267 SCV002534929 likely benign Fanconi anemia 2022-01-21 criteria provided, single submitter curation
Mayo Clinic Laboratories, Mayo Clinic RCV001800637 SCV002541386 uncertain significance not provided 2021-12-14 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000255908 SCV002556224 benign not specified 2023-12-15 criteria provided, single submitter clinical testing Variant summary: FANCA c.1874G>C (p.Cys625Ser) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0026 in 1612748 control chromosomes, predominantly at a frequency of 0.0031 within the Non-Finnish European subpopulation in the gnomAD database. The observed variant frequency within Non-Finnish European control individuals in the gnomAD database is approximately equal to the estimated maximal expected allele frequency for a pathogenic variant in FANCA causing Fanconi Anemia phenotype (0.0022) and the variant was found in 8 homozygotes, strongly suggesting that the variant is a benign polymorphism found primarily in populations of Non-Finnish European origin. c.1874G>C has been reported in the literature in at least two individuals affected with Fanconi Anemia, however in one case it was not considered to be pathogenic as it was reportedly located in cis downstream from a pathogenic variant and was also observed at a similar frequency in healthy controls (Castella_2011, De Rocco_2014). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 21273304, 24584348, 34864095). Multiple submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 with conflicting assessments. Ten submitters have classified the variant as uncertain significance, six submitters classified it as benign/likely benign, and one classified it as pathogenic. Based on the evidence outlined above, the variant was classified as benign.
St. Jude Molecular Pathology, St. Jude Children's Research Hospital RCV000989672 SCV002584661 uncertain significance Fanconi anemia complementation group A 2023-07-11 criteria provided, single submitter clinical testing The FANCA c.1874G>C (p.Cys625Ser) missense change has a maximum subpopulation frequency of 0.39% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL predicts a deleterious effect on protein function, but to our knowledge this prediction has not been confirmed by functional studies. This variant has been reported in an individual with Fanconi anemia who also harbored a deletion of exons 18-20 in FANCA, however the phase of the two variants was not known (PMID: 21273304). In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance.
Revvity Omics, Revvity RCV000989672 SCV003833892 uncertain significance Fanconi anemia complementation group A 2022-06-07 criteria provided, single submitter clinical testing
CeGaT Center for Human Genetics Tuebingen RCV001800637 SCV004143610 likely benign not provided 2023-05-01 criteria provided, single submitter clinical testing FANCA: BS2
PreventionGenetics, part of Exact Sciences RCV003920022 SCV004736568 likely benign FANCA-related condition 2022-02-02 criteria provided, single submitter clinical testing This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications).
Leiden Open Variation Database RCV000989672 SCV001425811 pathogenic Fanconi anemia complementation group A 2020-02-28 no assertion criteria provided curation Curator: Arleen D. Auerbach. Submitter to LOVD: Arleen D. Auerbach.
Natera, Inc. RCV000989672 SCV001462951 benign Fanconi anemia complementation group A 2020-05-08 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.